Pykus Therapeutics, Inc. ("Pykus" or the "Company") announced that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia. The study is evaluating the use of Pykus'...

Daicel Arbor Biosciences, a company that offers tools and services to accelerate genomics and synthetic biology research, in collaboration with Element Biosciences, a life sciences company...

Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and...

IFF Pharma Solutions, a global leader in polymer innovations, announced the launch of Low Nitrite METHOCEL™ hydroxypropyl methylcellulose (HPMC), a range of low nitrite cellulose ethers developed to...

SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer therapeutics, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has approved its...

Hello Heart, the digital leader in preventive heart health, today introduced Hello Heart Pill Box, a proprietary smart pill box designed to improve medication adherence. This addition to Hello Heart’s...

George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to become Emerald Clinical Trials. 

After 50 years, a new era in itch relief has arrived. PBZ OTC Pyribenzamine Antihistamine Cream, the first new topical antihistamine in half a century, is set to launch in April at Target stores...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial...

IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target...

Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the...

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is...